San Francisco, Feb. 13, 2017 – Recardio, is participating in the BIO CEO & Investor Conference.
The Conference is one of the largest investor conferences focused on established and emerging publicly traded and selected private biotech companies. Since the event’s purpose is to support industry-wide success, it presents a broad and unbiased view of investment opportunities.
The BIO CEO & Investor Conference is held on February 13-14, 2017 at the Waldorf Astoria in New York.
The company presents and discusses its latest advancements from its drug-based regenerative therapy program.
More information about the clinical program is available by visiting the following link.
Recardio is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company has initiated a Phase 1/2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/